Terms Defined Elsewhere Clause Samples

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: “Acquisition Proposal” Section 7.2(b)(ii) “Agreement” Preamble

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below:

Terms Defined Elsewhere. As used in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Agreement Preamble Amendment to the Company Management Agreement Recitals Articles of Merger 2.2(b) Book-Entry Shares 3.3(b)(i) Cancelled Shares 3.1(b)(v) Certificate of Merger 2.2(b) Certificates 3.3(b)(i) Closing 2.2(a) Closing Date 2.2(a) Code Recitals Company Preamble Company Additional Dividend Amount 6.19(a) Company Affiliate 9.10(a) Company Board Recitals Company Board Recommendation Recitals Company Change of Recommendation 6.3(b) Company Common Stock 3.1(b)(i) Company Contracts 3.2(b) Company DER Consideration 3.2(b) Company Director Designee 2.6 Company Disclosure Letter Article IV Company Dividend Equivalent Right 3.2(b) Company Material Adverse Effect 4.1(a) Company Permits 4.9 Company Plans 4.10(a) Company SEC Documents 4.5(a) Company Series A Preferred Stock 3.1(b)(iii) Company Series B Preferred Stock 3.1(b)(iii) Company Series C Preferred Stock 3.1(b)(iii) Company Special Committee Recitals Company Stockholders Recitals Company Stockholders Meeting 4.4 Confidentiality Agreement 6.7(b) Creditors’ Rights 4.3(a) Delaware LLC Act 2.1 Delaware Secretary of State 2.2(b) e-mail 9.3 Effective Time 2.2(b) End Date 8.1(b)(ii) Exchange Agent 3.3(a) Exchange Fund 3.3(a) Forfeited Phantom Shares 3.2(a) GAAP 4.5(b) Indemnified Liabilities 6.10(a) Indemnified Persons 6.10(a) Joint Proxy Statement 4.4 Letter of Transmittal 3.3(b)(i) Leverage Covenants 6.1(a)(xiv) Maryland Courts 9.7(b) Maryland Department 2.2(b) Material Company Insurance Policies 4.17 Material Parent Insurance Policies 5.17 Merger Recitals Merger Filings 2.2(b) Merger Sub Preamble Merger Sub Sole Member Recitals MGCL 2.1 Operating Partnership 2.1 Parent Preamble Parent Additional Dividend Amount 6.19(b) Parent Affiliate 9.10(b) Parent Board Recitals Parent Board Recommendation 5.3(a) Parent Change of Recommendation 6.4(b) Parent Common Stock Issuance Recitals Parent Contracts 5.16(b) Parent Disclosure Letter Article V Parent Equity Plan 5.2(a) Parent Management Agreement Amendment Recitals Parent Manager Recitals Parent Material Adverse Effect 5.1(a) Parent Permits 5.9 Parent Plans 5.10(a) Parent SEC Documents 5.5(a) Parent Stock Issuance Recitals Parent Stockholders Recitals .pdf 9.5 Per Share Common Merger Consideration 3.1(b)(i) Per Share Preferred Merger Consideration 3.1(b)(iii) Per Share Preferred Series B Merger Consideration 3.1(b)(iii) Per Share Preferred...

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: “Adverse Action” Section 4.6.2 “Agreement” Recitals “Certificate of Merger” Section 2.4 “Certificates” Section 3.2.2

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: Acquisition 7.3(d) Agreement Preamble Apogent Preamble Apogent Balance Sheet 3.1(d)(iv) Apogent Benefit Plans 3.1(i)(i) Apogent Bylaws 3.1(a)(ii) Apogent Charter 3.1(a)(ii) Apogent Common Stock 2.1 Apogent Disclosure Schedule 3.1 Apogent Leased Real Property 3.1(r) Apogent Material Contract 3.1(q)(i) Apogent Option 2.1(d) Apogent Organizational Documents 3.1(a)(ii) Apogent Owned Real Property 3.1(r) Apogent Permits 3.1(g)(i) Apogent Preferred Stock 3.1(b)(i) Apogent Purchase Plan 2.1(d) Apogent Restricted Stock Unit 5.11(a)(ii) Apogent Rights 3.1(b)(i) Apogent Rights Agreement 3.1(b)(i) Apogent SEC Documents 3.1(d)(i) Apogent Shareholder Approval 3.1(c)(iii) Apogent Shareholders’ Meeting 5.1(b) Apogent Significant Subsidiaries 3.1(a)(iii) Apogent Stock Plans 3.1(b)(i) Apogent Subsidiary Organizational Documents 3.1(a)(ii) Apogent Termination Fee 7.3(a) Apogent Third Party Bidder 7.3(a)(i) Applicable Laws 3.1(g)(ii) Approval 3.1(i)(ii) Articles of Merger 1.3 Benefit Continuation Period 5.11(c) Benefit Plans 3.1(i)(i) CDA 4.2(c)(i) Certificates 2.2(b) Change of Recommendation 4.2(d)(ii) Closing 1.2 Closing Date 1.2 Code Recitals DFI 1.3 Effect 8.3(k) Effective Time 1.3 ERISA 3.1(i)(i) ERISA Affiliate 3.1(i)(v) Exchange Act 3.1(c)(v)(B)(2) Exchange Agent 2.2(a) (a) Exchange Ratio 2.1(a) FDA 3.1(g)(i)

Terms Defined Elsewhere. The following terms are defined herein in the sections identified below:

Terms Defined Elsewhere. The following terms are defined in this Agreement as follows: “Agreement” Preamble

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: “Agreement” Preamble “Automotives Business” Section 3.20(b) “Automotives Subsidiaries” Section 3.20(b) “Certificate of Merger” Section 1.4 “Certificates” Section 2.2(b) “Change of Recommendation” Section 5.4(e) “Closing” Section 1.4 “Closing Date” Section 1.4 “Company” Preamble “Company Acquisition Agreement” Section 5.4(e) “Company Benefit Plan” Section 3.11(a) “Company Board” Recitals “Company Board Recommendation” Recitals “Company Bylaws” Section 3.1 “Company Certificate” Section 3.1 “Company Common Stock” Section 3.3(a) “Company Disclosure Schedule” Article 3 “Company Employee” Section 5.8(a) “Company Financial Advisor” Section 3.23 “Company Financial Statements” Section 3.7 “Company Material Contract” Section 3.13(a) “Company Options” Section 2.4(a) “Company Permits” Section 3.6(a) “Company Preferred Stock” Section 3.3(a) “Company Representatives” Section 5.3(a) “Company SEC Documents” Section 3.7 “Company Stock Plans” Section 2.4(a) “Company Stockholder Approval” Section 3.26 “Company Termination Fee” Section 7.2(b)(i) “Company Warrants” Section 2.5 “Confidentiality Agreement” Section 5.3(b) “Covered Persons” Section 5.9(a) “Debt Financing” Section 4.9(b) “Debt Financing Commitments” Section 4.9(b) “D&O Insurance” Section 5.9(c) “DGCL” Recitals “Dissenting Shares” Section 2.3 “Effective Time” Section 1.4 “Environmental Claims” Section 3.15(a) “Equity Commitment Letter” Section 4.9(b) “Equity Financing” Section 4.9(b) “Equity Investors” Section 4.9(b) “Equivalent Coverage” Section 5.9(c) “ERISA” Section 3.11(a) “ERISA Affiliate” Section 3.11(a) “Exchange Act” Section 1.1(a) “Expense Reimbursement Fee” Section 7.2(b)(v) “Expiration Date” Section 1.1(d) “Extended Outside Date” Section 1.1(e) “Fairness Opinion” Section 3.23 “FCPA” Section 3.8(d) “Financing” Section 4.9(b) “Financing Alternative” Section 5.12(c) “Financing Commitments” Section 4.9(b) “Governmental Approval Condition” Annex I “Grant Date” 3.3 (b) “HSR Condition” Annex I “Inclusive Companies” Section 3.15(a) “Indemnification Agreements” Section 5.9(a) “Independent Director Approval” Section 1.8(d) “Independent Directors” Section 1.8(b) “Initial Expiration Date” Section 1.1(d) “Initial Outside Date” Section 1.1(e) “Lease Agreements” Section 3.13(a) “Leased Real Property” Section 3.21(b) “Legal Proceeding” Section 3.14 “Maximum Amount” Section 5.9(c) “Merger” Recitals “Merger Consideration” Section 2.1(a) “Minim...